NCT00616733

12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

An Open-label, Escalating-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Daiichi Sankyo · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	CS-0777 tablets	0.1 mg, once-weekly, for 12 weeks
DRUG	CS-0777 tablets	0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
DRUG	CS-0777 tablets	0.6 mg, once-weekly or once every 2 weeks, for 12 weeks

Timeline

• Start date: 2008-03-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2008-02-15
• Last updated: 2011-03-10

Locations

5 sites across 1 country: United States